14 CLINICAL STUDIES
The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by 10 mg as needed, 60 minutes prior to sexual activity Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability For patients taking potent or moderate inhibitors of CYP3A4, dose adjustment is as follows: Ritonavir: no more than 2.5 mg in a 72-hour period Indinavir, saquinavir, atazanavir, ketoconazole 400 mg daily, itraconazole 400 mg daily, clarithromycin: no more than 2.5 mg in a 24-hour period Ketoconazole 200 mg daily, itraconazole 200 mg daily, erythromycin: no more than 5 mg in a 24-hour period. Cardiovascular effects - patients should not use Vardenafil if sex is inadvisable due to cardiovascular status. Risk of priapism - in the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Effects on the eye - patients should stop treatment and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be sign of nonarteritic anterior ischemic optic neuropathy (NAION). Use with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a "crowed" optic disc may also be at an increased risk of NAION. Sudden hearing loss - patients should stop treatment and seek medical attention in the event of sudden decrease or loss in hearing Alpha-blockers - caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting) QT prolongation - patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using Vardenafil Other erectile dysfunction therapies - the safety and efficacy of vardenafil used in combination with other treatments for ED have not been studied. Signs and symptoms may include reversible back pain/myalgia and/or "abnormal vision." Standard supportive measures should be taken as required. Renal dialysis is not expected to accelerate clearance as vardenafil is highly bound to plasma proteins and not significantly eliminated in the urine. Pregnancy: Pregnancy Category B; not indicated for use in women.
5.1 Cardiovascular Effects
Effects on Blood Pressure and Heart Rate when Combined with Nitrates: A study was conducted in which the blood pressure and heart rate response to 0.4 mg nitroglycerin (NTG) sublingually was evaluated in 18 healthy subjects following pretreatment with vardenafil 20 mg at various times before NTG administration. Vardenafil 20 mg caused an additional time-related reduction in blood pressure and increase in heart rate in association with NTG administration. The blood pressure effects were observed when vardenafil 20 mg was dosed 1 or 4 hours before NTG and the heart rate effects were observed when 20 mg was dosed 1, 4, or 8 hours before NTG. Additional blood pressure and heart rate changes were not detected when vardenafil 20 mg was dosed 24 hours before NTG. Because the disease state of patients requiring nitrate therapy is anticipated to increase the likelihood of hypotension, the use of vardenafil by patients on nitrate therapy or on nitric oxide donors is contraindicated.
Vascular damage
Blood Pressure cheap levitra oral jelly online Effects in Patients on Stable Alpha-Blocker Treatment: Three clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment, consisting of alfuzosin, tamsulosin or terazosin. Study 1: This study was designed to evaluate the effect of 5 mg vardenafil compared to placebo when administered to BPH patients on chronic alpha-blocker therapy in two separate cohorts: tamsulosin 0.4 mg daily (cohort 1, n=21) and terazosin 5 or 10 mg daily (cohort 2, n=21). The design was a randomized, double blind, cross-over study with four treatments: vardenafil 5 mg or placebo administered simultaneously with the alpha-blocker and vardenafil 5 mg or placebo administered 6 hours after the alpha- blocker. Blood pressure and pulse were evaluated over the 6-hour interval after vardenafil dosing. One patient after simultaneous treatment with 5 mg vardenafil and 10 mg terazosin exhibited symptomatic hypotension with standing blood pressure of 80/60 mmHg occurring one hour after administration and subsequent mild dizziness and moderate lightheadedness lasting for 6 hours.
Chemicals and reagents
For vardenafil and placebo, five and two patients, respectively, experienced a decrease in standing systolic blood pressure (SBP) of >30 mmHg following simultaneous administration of terazosin. Hypotension was not observed when vardenafil 5 mg and terazosin were administered 6 hours apart. Following simultaneous administration of vardenafil 5 mg and tamsulosin, two patients had a standing SBP of <85 mmHg. A decrease in standing SBP of >30 mmHg was observed in two patients on tamsulosin receiving simultaneous vardenafil and in one patient receiving simultaneous placebo treatment. When tamsulosin and vardenafil 5 mg were separated by 6 hours, two patients had a standing SBP <85 mmHg and one patient had a decrease in SBP of >30 mmHg. Nursing Mothers: Not indicated for use in women. Renal Impairment: Do not use in patients on renal dialysis; no dosage adjustment necessary in patients with ClCr 30-80 mL/min. Hepatic Impairment: Do not use in patients with severe impairment (Child-Pugh C); dosage adjustment is necessary in patients with moderate impairment. Pediatric Patients: Not indicated for use in pediatric patients; safety and efficacy have not been established in this population. Geriatric Patients: No differences in safety and effectiveness noted between elderly (≥65 years of age) and younger patients. However, due to increased vardenafil concentrations in the elderly, a starting dose of 5 mg should be considered in the elderly. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum.
- Liquid Levitra is an oral medication for erectile dysfunction.
- It is formulated for faster absorption than tablets.
- Typically administered with a liquid dose for convenience.
Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection.
- Consumers should avoid alcohol when using liquid Levitra.
- Do not exceed the prescribed dose to prevent side effects.
- Keep out of reach of children due to potential misuse.
The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Generic | 20mg | 60 + 6 Pills | 131.11€ 124.87€ | |
| Levitra Professional | 20mg | 30 Pills | 119.12€ 113.45€ | |
| Levitra Generic | 60mg | 20 Pills | 81.30€ 77.43€ | |
| Levitra Generic | 60mg | 10 Pills | 47.42€ 45.16€ | |
| Levitra Original | 20mg | 8 Pills | 65.05€ 61.95€ | |
| Levitra Generic | 40mg | 60 + 4 Pills | 162.37€ 154.64€ | |
| Levitra Generic | 20mg | 180 + 10 Pills | 293.10€ 279.14€ | |
| Levitra Original | 20mg | 14 + 2 Pills | 102.27€ 97.40€ | |
| Levitra Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Levitra Original | 20mg | 120 + 8 Pills | 528.19€ 503.04€ | |
| Levitra Generic | 10mg | 90 + 8 Pills | 150.58€ 143.41€ | |
| Levitra Original | 20mg | 12 Pills | 81.99€ 78.09€ | |
| Levitra Generic | 20mg | 120 + 10 Pills | 224.15€ 213.48€ |
The most abundant PDE in the human corpus cavernosum is the cGMP-specific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
How is Levitra used?
Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 has no effect in the absence of sexual stimulation.
| Ingredient | Concentration | Purpose | Notes |
|---|---|---|---|
| Vardenafil Hydrochloride | 20 mg/mL | Active component for erectile dysfunction relief | Prescribed dose varies |
| Glycerin | 10% | Solvent and base | Enhances absorption |
| Purified Water | Q.S. to 100% | Diluent | Ensures stability |
| Flavoring Agents | - | Improves taste | Commonly mint or berry |
In vitro studies have shown that vardenafil is a selective inhibitor of PDE5.
- The medication is available by prescription only.
- Liquid form allows flexible dosing compared to tablets.
- Usage instructions should be followed exactly.
The inhibitory effect of vardenafil is more selective on PDE5 than for other known phosphodiesterases (>15-fold relative to PDE6, >130-fold relative to PDE1, >300-fold relative to PDE11, and >1,000-fold relative to PDE2, 3, 4, 7, 8, 9, and 10). In a clinical pharmacology study of patients with erectile dysfunction, single doses of vardenafil 20 mg caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Following multiple dosing for 31 days, similar blood pressure responses were observed on Day 31 as on Day 1. Vardenafil may add to the blood pressure lowering effects of antihypertensive agents. Effects on Blood Pressure and Heart Rate when Combined with Nitrates: A study was conducted in which the blood pressure and heart rate response to 0.4 mg nitroglycerin (NTG) sublingually was evaluated in 18 healthy subjects following pretreatment with vardenafil 20 mg at various times before NTG administration. Vardenafil 20 mg caused an additional time-related reduction in blood pressure and increase in heart rate in association with NTG administration. The blood pressure effects were observed when vardenafil 20 mg was dosed 1 or 4 hours before NTG and the heart rate effects were observed when 20 mg was dosed 1, 4, or 8 hours before NTG. Additional blood pressure and heart rate changes were not detected when vardenafil 20 mg was dosed 24 hours before NTG. Because the disease state of patients requiring nitrate therapy is anticipated to increase the likelihood of hypotension, the use of vardenafil by patients on nitrate therapy or on nitric oxide donors is contraindicated. Blood Pressure cheap levitra oral jelly online Effects in Patients on Stable Alpha-Blocker Treatment: Three clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment, consisting of alfuzosin, tamsulosin or terazosin. Study 1: This study was designed to evaluate the effect of 5 mg vardenafil compared to placebo when administered to BPH patients on chronic alpha-blocker therapy in two separate cohorts: tamsulosin 0.4 mg daily (cohort 1, n=21) and terazosin 5 or 10 mg daily (cohort 2, n=21). The design was a randomized, double blind, cross-over study with four treatments: vardenafil 5 mg or placebo administered simultaneously with the alpha-blocker and vardenafil 5 mg or placebo administered 6 hours after the alpha- blocker. Blood pressure and pulse were evaluated over the 6-hour interval after vardenafil dosing.
In case of emergency/overdose
There were no severe adverse events related to hypotension reported during the study. Study 2: This study was designed to evaluate the effect of 10 mg vardenafil (stage 1) and 20 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=23) on stable therapy with tamsulosin 0.4 mg or 0.8 mg daily for at least four weeks. The design was a randomized, double blind, two-period cross- over study. Vardenafil or placebo was given simultaneously with tamsulosin. One patient experienced a decrease from baseline in standing SBP of >30 mmHg following vardenafil 10 mg.
Preparing the injection
There were no other instances of outlier blood pressure values (standing SBP <85 mmHg or decrease from baseline in standing SBP of >30 mmHg). Three patients reported dizziness following vardenafil 20 mg. Study 3: This study was designed to evaluate the effect of single doses of 5 mg vardenafil (stage 1) and 10 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=24) on stable therapy with alfuzosin 10 mg daily for at least four weeks. The design was a randomized, double blind, 3-period cross- over study. Vardenafil or placebo was administered 4 hours after the administration of alfuzosin.
Determination of phosphodiesterase type V inhibitors in wastewater by direct injection followed by liquid chromatography coupled to tandem mass spectrometry
Blood pressure and pulse were evaluated over a 10-hour interval after dosing of vardenafil or placebo. One patient experienced decreases from baseline in standing systolic blood pressure >30 mm Hg after administration of vardenafil 5 mg film-coated tablet and vardenafil 10 mg film-coated tablet. No instances of standing systolic blood pressure <85 mm Hg were observed during this study. Four patients, one dosed with placebo, two dosed with vardenafil 5 mg film-coated tablets and one dosed with vardenafil 10 mg film-coated tablets, reported dizziness. Blood pressure effects (standing SBP) in normotensive men on a stable dose of alfuzosin 10 mg following administration of vardenafil 5 mg, vardenafil 10 mg, or placebo separated by 4 hours Blood pressure effects in normotensive men after forced titration with alpha-blockers: Two randomized, double blind, placebo-controlled clinical pharmacology studies with healthy normotensive volunteers (age range, 45-74 years) were performed after forced titration of the alpha-blocker terazosin to 10 mg daily over 14 days (n=29), and after initiation of tamsulosin 0.4 mg daily for five days (n=24). One patient after simultaneous treatment with 5 mg vardenafil and 10 mg terazosin exhibited symptomatic hypotension with standing blood pressure of 80/60 mmHg occurring one hour after administration and subsequent mild dizziness and moderate lightheadedness lasting for 6 hours. For vardenafil and placebo, five and two patients, respectively, experienced a decrease in standing systolic blood pressure (SBP) of >30 mmHg following simultaneous administration of terazosin. Hypotension was not observed when vardenafil 5 mg and terazosin were administered 6 hours apart. Following simultaneous administration of vardenafil 5 mg and tamsulosin, two patients had a standing SBP of <85 mmHg. A decrease in standing SBP of >30 mmHg was observed in two patients on tamsulosin receiving simultaneous vardenafil and in one patient receiving simultaneous placebo treatment.
6.2 Postmarketing Experience
When tamsulosin and vardenafil 5 mg were separated by 6 hours, two patients had a standing SBP <85 mmHg and one patient had a decrease in SBP of >30 mmHg.
ED Medications: Cialis, Levitra, Viagra
The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by 10 mg as needed, 60 minutes prior to sexual activity Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability For patients taking potent or moderate inhibitors of CYP3A4, dose adjustment is as follows: Ritonavir: no more than 2.5 mg in a 72-hour period Indinavir, saquinavir, atazanavir, ketoconazole 400 mg daily, itraconazole 400 mg daily, clarithromycin: no more than 2.5 mg in a 24-hour period Ketoconazole 200 mg daily, itraconazole 200 mg daily, erythromycin: no more than 5 mg in a 24-hour period. Cardiovascular effects - patients should not use Vardenafil if sex is inadvisable due to cardiovascular status. Risk of priapism - in the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Effects on the eye - patients should stop treatment and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be sign of nonarteritic anterior ischemic optic neuropathy (NAION).
What went well
Use with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a "crowed" optic disc may also be at an increased risk of NAION. Sudden hearing loss - patients should stop treatment and seek medical attention in the event of sudden decrease or loss in hearing Alpha-blockers - caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting) QT prolongation - patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using Vardenafil Other erectile dysfunction therapies - the safety and efficacy of vardenafil used in combination with other treatments for ED have not been studied. Signs and symptoms may include reversible back pain/myalgia and/or "abnormal vision." Standard supportive measures should be taken as required.
How effective are vardenafil and tadalafil for erectile dysfunction?
Renal dialysis is not expected to accelerate clearance as vardenafil is highly bound to plasma proteins and not significantly eliminated in the urine. Pregnancy: Pregnancy Category B; not indicated for use in women. Nursing Mothers: Not indicated for use in women. Renal Impairment: Do not use in patients on renal dialysis; no dosage adjustment necessary in patients with ClCr 30-80 mL/min. Hepatic Impairment: Do not use in patients with severe impairment (Child-Pugh C); dosage adjustment is necessary in patients with moderate impairment. There were no severe adverse events related to hypotension reported during the study. Study 2: This study was designed to evaluate the effect of 10 mg vardenafil (stage 1) and 20 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=23) on stable therapy with tamsulosin 0.4 mg or 0.8 mg daily for at least four weeks.
Vardenafil hydrochloride Trihydrate
Pediatric Patients: Not indicated for use in pediatric patients; safety and efficacy have not been established in this population. Geriatric Patients: No differences in safety and effectiveness noted between elderly (≥65 years of age) and younger patients. However, due to increased vardenafil concentrations in the elderly, a starting dose of 5 mg should be considered in the elderly. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum.
Urethral suppository (Muse)
The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMP-specific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 has no effect in the absence of sexual stimulation. In vitro studies have shown that vardenafil is a selective inhibitor of PDE5.
What should I know about vardenafil before taking it?
The inhibitory effect of vardenafil is more selective on PDE5 than for other known phosphodiesterases (>15-fold relative to PDE6, >130-fold relative to PDE1, >300-fold relative to PDE11, and >1,000-fold relative to PDE2, 3, 4, 7, 8, 9, and 10). In a clinical pharmacology study of patients with erectile dysfunction, single doses of vardenafil 20 mg caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Following multiple dosing for 31 days, similar blood pressure responses were observed on Day 31 as on Day 1. Vardenafil may add to the blood pressure lowering effects of antihypertensive agents. The design was a randomized, double blind, two-period cross- over study.
- Liquid Levitra should be measured with a proper device.
- Avoid mixing with hot liquids to prevent degradation.
- Keep the medication stored at room temperature.
Vardenafil or placebo was given simultaneously with tamsulosin. One patient experienced a decrease from baseline in standing SBP of >30 mmHg following vardenafil 10 mg. There were no other instances of outlier blood pressure values (standing SBP <85 mmHg or decrease from baseline in standing SBP of >30 mmHg). Three patients reported dizziness following vardenafil 20 mg. Study 3: This study was designed to evaluate the effect of single doses of 5 mg vardenafil (stage 1) and 10 mg vardenafil (stage 2) compared to placebo, when administered to a single cohort of BPH patients (n=24) on stable therapy with alfuzosin 10 mg daily for at least four weeks. The design was a randomized, double blind, 3-period cross- over study. Vardenafil or placebo was administered 4 hours after the administration of alfuzosin. Blood pressure and pulse were evaluated over a 10-hour interval after dosing of vardenafil or placebo. One patient experienced decreases from baseline in standing systolic blood pressure >30 mm Hg after administration of vardenafil 5 mg film-coated tablet and vardenafil 10 mg film-coated tablet.
5.14 Sexually Transmitted Disease
No instances of standing systolic blood pressure <85 mm Hg were observed during this study. Four patients, one dosed with placebo, two dosed with vardenafil 5 mg film-coated tablets and one dosed with vardenafil 10 mg film-coated tablets, reported dizziness. Blood pressure effects (standing SBP) in normotensive men on a stable dose of alfuzosin 10 mg following administration of vardenafil 5 mg, vardenafil 10 mg, or placebo separated by 4 hours Blood pressure effects in normotensive men after forced titration with alpha-blockers: Two randomized, double blind, placebo-controlled clinical pharmacology studies with healthy normotensive volunteers (age range, 45-74 years) were performed after forced titration of the alpha-blocker terazosin to 10 mg daily over 14 days (n=29), and after initiation of tamsulosin 0.4 mg daily for five days (n=24).